NASDAQ:AKRO Akero Therapeutics Q2 2024 Earnings Report $52.08 -2.25 (-4.14%) Closing price 04:00 PM EasternExtended Trading$52.74 +0.66 (+1.27%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Akero Therapeutics EPS ResultsActual EPS-$0.81Consensus EPS -$0.90Beat/MissBeat by +$0.09One Year Ago EPSN/AAkero Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAkero Therapeutics Announcement DetailsQuarterQ2 2024Date8/9/2024TimeBefore Market OpensConference Call DateFriday, August 9, 2024Conference Call Time7:00AM ETUpcoming EarningsAkero Therapeutics' Q2 2025 earnings is scheduled for Friday, August 8, 2025, with a conference call scheduled on Monday, August 11, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Akero Therapeutics Earnings HeadlinesCorcept Seeks FDA Approval for Relacorilant in Ovarian CancerJuly 15 at 11:18 PM | msn.comAKRO - Akero Therapeutics Inc Valuation - MorningstarJuly 3, 2025 | morningstar.comMThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 18 at 2:00 AM | Brownstone Research (Ad)Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t PleasedJune 13, 2025 | msn.comAkero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 3, 2025 | globenewswire.comAkero Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comSee More Akero Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Akero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akero Therapeutics and other key companies, straight to your email. Email Address About Akero TherapeuticsAkero Therapeutics (NASDAQ:AKRO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for patients with serious metabolic diseases. The company’s lead candidate, efruxifermin, is an Fc-fusion analog of fibroblast growth factor 21 (FGF21) designed to improve lipid metabolism, reduce liver fat, and address the underlying drivers of nonalcoholic steatohepatitis (NASH). Akero’s research platform leverages engineered hormone analogs to target key metabolic pathways implicated in NASH, type 2 diabetes, and other related disorders. In addition to its efruxifermin program, Akero maintains a pipeline of next-generation FGF21-based molecules at various stages of preclinical and clinical development. The company’s approach aims to balance efficacy and tolerability by optimizing pharmacokinetics and receptor engagement, with the goal of delivering durable improvements in liver histology and metabolic function. Akero has reported promising data from Phase 2 studies in NASH, demonstrating reductions in hepatic fat content, improvements in fibrosis markers, and favorable safety profiles. Founded in 2016 and headquartered in Boston, Massachusetts, Akero Therapeutics operates within major biotech hubs and collaborates with academic institutions and strategic partners worldwide. The company’s leadership team combines expertise in endocrinology, hepatology, and drug development, with a focus on advancing therapies that address the growing global burden of metabolic liver disease. Akero is committed to rigorous clinical evaluation and aims to bring first-in-class or best-in-class treatments to patients with limited therapeutic options.Written by Jeffrey Neal JohnsonView Akero Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
